- Immune thrombocytopenia in a patient with essential thrombocythemia after SARS-CoV-2 infection: A case report2023 | Third Faculty of Medicine
- The results of the of patiens with essentials thrombocythemia and other myeloproliferation-related thrombocythemia - a report of patients treated with Thromboreductin(R)2009 | Publication without faculty affiliation
- Anagrelide in the treatment of essential thrombocythemia2004 | First Faculty of Medicine
- Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia2005 | First Faculty of Medicine
- Most pediatric patients with essential thrombocythemia show hypersensitivity to erythropoietin in vitro, with rare JAK2 V617F-positive erythroid colonies2008 | Second Faculty of Medicine
- The results of patients with essentials thrombocythemia and other myeloproliferation-related thrombocythemia - a report of patients treated with Thromboreductin +22009 | Faculty of Medicine in Hradec Králové
- Takotsubo cardiomyopathy in a patient with essential thrombocythemia treated with anagrelide: Case report2018 | First Faculty of Medicine
- Functional analysis of germline ETV6 W380R mutation causing inherited thrombocytopenia and secondary acute lymphoblastic leukemia or essential thrombocythemia2021 | Second Faculty of Medicine
- Allogenic transplantation of haemoplastic progenitor cells in chronic myeloproliferations2006 | Publication without faculty affiliation
- Allogenic transplantation of haemoplastic progenitor cells in chronic myeloproliferations2006 | First Faculty of Medicine
- Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups2020 | Publication without faculty affiliation
- Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b2022 | Publication without faculty affiliation
- The effectiveness of anagrelide treatment in patients with Ph-negative myeloproliferative diseases: Influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 20122013 | Faculty of Medicine in Hradec Králové
- The WHO 2008 classification of Ph-myeloproliferative disorders: statement of the Czech MPD Working Group2008 | Second Faculty of Medicine
- Analysis of risk factors: The rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia2006 | Second Faculty of Medicine
- Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases - principles and rationale of CZEMP recommendations2011 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study2020 | Publication without faculty affiliation
- PH negative myeloproliferative neoplasms in Czech haematological centres - MIND analysis2021 | Faculty of Medicine in Hradec Králové
- Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases - principles and rationale of CZEMP recommendations2011 | Second Faculty of Medicine
- Analysis of risk factors: The rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia2006 | First Faculty of Medicine
- Analysis of risk factors: The rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia2006 | Faculty of Physical Education and Sport
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. CINC424A2401Publication without faculty affiliation
- Report of University Hospital Hradec Králové to the clinical trial protocol No: GS-US-352-0101Publication without faculty affiliation
- Analysis of risk factor : the rationale of the guildelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia2006 | First Faculty of Medicine
- Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells2010 | Central Library of Charles University
